Parkinson's Action Network Announces $75,000 in Two New Advocacy Prizes for Researchers

PARKINSON’S ACTION NETWORK ANNOUNCES $75,000
IN TWO NEW ADVOCACY PRIZES FOR RESEARCHERS

Call for Nominations
More information is available by contacting Elizabeth Kwasnik at ekwasnik@parkinsonsaction.org or calling 202.638.4101 x111.  Nominations will be accepted through July 9, 2012.  UPDATE:  Nominations are now closed.

Call for Nominations (PDF)
Nomination Form - Self (WORD)
Nomination Form - Other (WORD)

WASHINGTON, D.C.; FRIDAY, JUNE 1, 2012 –
The Parkinson’s Action Network (PAN) announced today it has established two new prizes to honor outstanding advocacy in the scientific community:

Parkinson’s Action Network Researcher Advocacy Prize is a $50,000 prize supported by UCB and given to an established Parkinson’s disease researcher in the U.S. who has excelled in biomedical research advocacy and community outreach.  To be eligible, nominee must be a current recipient of an NIH Research Project Grant (R01) or equivalent as the principal investigator (PI) in the field of Parkinson’s disease.

Parkinson’s Action Network Postdoctoral Advocacy Prize, a $25,000 prize supported by Teva CNS, will be given to a postdoctoral Parkinson’s disease researcher in the U.S. who has excelled in biomedical research advocacy and community outreach.  To be eligible, nominee must be a postdoctoral Parkinson’s disease researcher (Ph.D.s ≤ 5 years from earning degree; M.D.s ≤ 5 years from completion of residency or fellowship training) who has excelled in biomedical research advocacy and community outreach.

The prizes will be presented at PAN’s annual Morris K. Udall Awards Dinner on October 3, 2012.  The Parkinson’s Action Network Researcher Advocacy Prize is funded by a grant from UCB.  The Parkinson’s Action Network Postdoctoral Advocacy Prize is supported by Teva CNS as part of their Platinum sponsorship of PAN’s annual Udall Awards Dinner.

“Now more than ever before, we need strong federal biomedical research funding and policy support for people with Parkinson’s, and advocacy is critical to making our voices heard,” said Parkinson’s Action Network CEO Amy Comstock Rick.  “Researchers who work day in and day out on understanding Parkinson’s disease so that we may one day find a cure are tremendously important voices in the national discussion about the importance of biomedical research.  In creating these two new prizes, we hope to encourage more researchers and scientists to become more engaged, vocal Parkinson’s advocates.  We are grateful to Teva CNS and UCB for their pioneering support of our organization, and in funding these prizes,” she added.

Nominated researchers should have experience in advocacy, which includes, but is not limited to:

  • Meeting with, writing, emailing, or calling Members of Congress or state or local policy makers regarding legislative issues that are important to the Parkinson’s community;
  • Speaking to a lay audience such as a Parkinson’s support group, other community groups, or a local high school about your research, Parkinson’s disease, or the role of basic and translational research in therapy development and the importance of federally funded biomedical research;
  • Working with community health organizations such as local hospitals, neurology offices, or senior centers to raise awareness of Parkinson’s disease; and 
  • Submitting Parkinson’s-related Letters to the Editor or articles for the public in local newspapers or newsletters.

About the Parkinson’s Action Network
The Parkinson’s Action Network is the unified voice of the Parkinson’s community advocating for better treatments and a cure.  In partnership with other Parkinson’s organizations and its powerful grassroots network, PAN educates the public and government leaders on better policies for research and an improved quality of life for people living with Parkinson’s.  For more information about PAN, go to parkinsonsaction.org.

#   #   #

Media Contact:
Carol Blymire, Director of Communications
cblymire@parkinsonsaction.org
202.638.4101 x113 (office)
301.332.8090 (cell)